Study identifies risk factors for uveitis in a PsA cohort

Key clinical point: The risk for uveitis was increased by more than double in patients with psoriatic arthritis (PsA), with past uveitis events and etanercept treatment being significant risk factors.

Major finding: The risk for uveitis was higher in patients with PsA vs matched control individuals without PsA (adjusted hazard ratio 2.38; 95% CI 1.80-3.15). Among patients with PsA, past events of uveitis (adjusted odds ratio [aOR] 136.4; 95% CI 27.38-679.88) and treatment with etanercept (aOR 2.57; 95% CI 1.45-4.57) were associated with an increased risk for uveitis.

Study details: This retrospective matched cohort study included 6147 patients with newly diagnosed PsA and 23,999 matched control individuals without PsA.

,

Disclosures: This study did not disclose the funding source. The authors declared no conflicts of interest.

Source: Hijazi N et al. The risk factors for uveitis among psoriatic arthritis patients: A population-based cohort study. Clin Rheumatol. 2023 (Dec 11). doi: 10.1007/s10067-023-06834-y